



DOCKET NO: L00461.70125.US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Old et al.
Serial No.: 10/054,683
Confirmation No.: 5148
Filed: January 22, 2002
For: CANCER-TESTIS ANTIGENS

Examiner: Unknown
Art Unit: 1651

RECEIVED
JAN 6 2003
TECH CENTER 1600
U.S. PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the 31 day of January, 2003.

June Watson
June Watson

Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith are the following documents:

Information Disclosure Statement
 Form PTO-1449 and References Cited
 Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

No check is enclosed. If a fee is determined to be required, the balance may be charged to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,
Old et al., Applicant

John R. Van Amsterdam
John R. Van Amsterdam, Reg. No. 40,212
Wolff, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210
Telephone: (617) 720-3500

Docket No. L00461.70125.US

Date: January 3, 2003

xNDD



DOCKET NO: L00461.70125.US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant: Old et al.
Serial No.: 10/054,683
Confirmation No.: 5148
Filed: January 22, 2002
For: CANCER-TESTIS ANTIGENS

Examiner: Unknown
Art Unit: 1651

RECEIVED
JAN 11 2003
TECH CENTER 1600 290C

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the 3rd day of January, 2003.


June Watson

Commissioner for Patents
Washington, D.C. 20231

**STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing date of a first Office Action on the merits in the above-identified case.

No fee or certification is required.

PART II - Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.



Serial No.: 10/054,683

Art Unit: 1651

The Applicant hereby makes the following additional information of record in the above-identified application:

PART III: Explanation of Non-English Language References and Remarks Concerning Other Information Cited

The following is a concise explanation of the relevance of each non-English language reference listed on the attached form PTO-1449 (modified):

The following are remarks concerning the other information cited:

PART IV: Remarks


A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached form PTO-1449 (modified). It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.



Serial No.: 10/054,683

Art Unit: 1651

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,
Old, et al., Applicant


John R. Van Amsterdam, Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210
Telephone (617) 720-3500

Docket No. L00461.70125.US

Date: January 3, 2003

xNDD

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 10/054,683	DOCKET NO.: L00461.70125.US
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: January 22, 2002	Confirmation No.: 8463
		APPLICANT: Old et al.	
Sheet	1	of	GROUP ART UNIT: 1651
		EXAMINER: Unknown	

JAN 06 2003
U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A1	5,698,396		Pfreundschuh	12-16-1991
					JAN 07 2003

RECEIVED
TECH CENTER 1600/2800

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	TRANSLATION (Y/N)
	C1	ACEVEDO et al., <i>Cancer</i> 76: 1467-1475 (1995)	
	C2	ANTONESCU et al., <i>Hum Pathol.</i> 33(2):225-9 (2002)	
	C3	BABA et al., <i>J Biochem</i> 1994; 269:10133-10140	
	C4	BEARD, J., <i>Lancet</i> 1:281-203 (1905)	
	C5	BOËL et al., <i>Immunity</i> 2: 167-175 (1995)	
	C6	BOYSE and OLD, <i>Ann Rev Genet</i> 3: 269-290 (1969)	
	C7	BOYSE et al., <i>Proc Royal Soc Brit</i> 170: 175-193 (1968)	
	C8	BRASSEUR et al., <i>Int J Cancer</i> 1995; 63 :375-380	✓
	C9	BRINKMANN et al., <i>Proc Natl Acad Sci USA</i> 95:10757-62 (1998)	
	C10	CARSWELL et al., <i>Proc Natl Acad Sci USA</i> 72: 3666-3670 (1975)	✓
	C11	CHEN et al., <i>Proc Natl Acad Sci USA</i> 95: 6919-6923 (1998)	✓
	C12	CHEN et al., <i>Proc. Natl. Acad. Sci USA</i> 94: 1914-1918 (1997)	✓
	C13	DALMAU et al., <i>Brain</i> 122: 27-39 (1999)	✓
	C14	DE BACKER et al., <i>Cancer Res</i> 59: 3157-65 (1999)	✓
	C15	DE LEO et al., <i>Proc Natl Acad Sci USA</i> 76: 2420-2424 (1979)	✓
	C16	DE PLAEN et al., <i>Immunogenetics</i> 40: 360-369 (1994)	✓
	C17	DE SMET et al., <i>Proc Natl Acad Sci USA</i> 93:7149-7153 (1996)	✓
	C18	DIRNHOFER et al., <i>Hum Path</i> 29: 377-382 (1998)	
	C19	DOTZLAW et al., <i>Mol Endocrinol.</i> 6:773-85 (1992)	
	C20	DROPCHO et al., <i>Proc Natl Acad Sci U S A</i> 84:4552-56 (1987)	✓
	C21	EICHMÜLLER et al., <i>Proc Natl Acad Sci USA</i> 98: 629-634 (2001)	✓
	C22	GAUGLER et al., <i>J. Exp. Med.</i> 179:921-30 (1994)	✓
	C23	GURCHOT, C., <i>Oncology</i> 31: 310-333 (1975)	✓
	C24	GÜRE et al., <i>Int. J. Cancer</i> 72: 965-971 (1997)	✓
	C25	GÜRE et al., <i>Int. J. Cancer</i> 85: 726-732 (2000)	✓
	C26	ILES and CHARD, <i>J Urol</i> 145 :453-458 (1991)	✓
	C27	JÄGER et al., <i>Proc Natl Acad Sci USA</i> 97: 4760-4765 (2000)	✓
	C28	JUNGBLUTH et al., <i>British Journ Cancer</i> 83: 493-497 (2000)	
	C29	JUNGBLUTH et al., <i>German Soc for Path. Submitted</i> 2001	✓
	C30	JUNGBLUTH et al., <i>Int J Cancer</i> 85 :460-5 (2000)	✓
	C31	JUNGBLUTH et al., <i>Int J Cancer</i> 92:856-860 (2001)	✓

INFORMATION DISCLOSURE
STATEMENT BY APPLICANTJAN 06 2003
SEARCHED & INDEXED
TRADEMAKES

FILING DATE: January 22, 2002

Confirmation No.: 8463

APPLICANT: Old et al.

GROUP ART UNIT: 1651

EXAMINER: Unknown

Sheet 2 of 2

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C32	JUNGBLUTH et al., <i>Int J Cancer</i> 94(2):252-6 (2001) ✓	
	C33	JUNGBLUTH et al., <i>Mod Path.</i> In press 2001 ✓	RECEIVED JAN 07 2003 TECH CENTER 1600-2900
	C34	KNUTH et al., <i>Proc Natl Acad Sci USA</i> 81: 3511-3515 (1984) ✓	
	C35	KURASHIGE et al., <i>Cancer Res.</i> 61:4671-4674 (2001) ✓	
	C36	LETHE et al., <i>Int J Cancer</i> 76:903-908 (1998) ✓	
	C37	LILLY et al., <i>Lancet</i> ii:1207-1209 (1965) ✓	
	C38	LOGING et al., <i>Genome Res</i> 10:1393-1402 (2000) ✓	
	C39	LUCAS et al., <i>Cancer Res</i> 58: 743-752 (1998) ✓	
	C40	LUCAS et al., <i>Int. J. Cancer</i> 87:55-60 (2000) ✓	
	C41	MACH et al., <i>Immunol Rev.</i> 138:207-21 (1994) ✓	
	C42	MARTELANGE et al., <i>Cancer Res</i> 60: 3848-3855 (2000) ✓	
	C43	MEUWISSEN et al., <i>EMBO J</i> 1992;11: 5091-5100 ✓	
	C44	MUSCATELLI et al., <i>Proc Natl Acad Sci USA</i> 92: 4987-4991 (1995) ✓	
	C45	NAGAI et al., <i>J. Biol. Chem.</i> 274:11053-9 (1999) ✓	
	C46	OLD and CHEN, <i>J Exp Med</i> 187:1163-1167 (1998) ✓	
	C47	OLD, L., <i>Cancer Res</i> 41: 361-375 (1981) ✓	
	C48	ONO et al., <i>Proc Natl Acad Sci USA</i> 98:3 282-3287 (2001) ✓	
	C49	PATARD et al., <i>Int J Cancer</i> 64:60-64 (1995) ✓	
	C50	PRIMAKOFF et al., <i>Trends Genet.</i> 16:83-7 (2000) ✓	
	C51	ROLDAN, E.R., <i>Front Biosci.</i> 3:D1109-19 (1998) ✓	
	C52	SAHIN et al., <i>Clin Cancer Res</i> 10: 3916-3922 (2000) ✓	
	C53	SAHIN et al., <i>Proc Natl Acad Sci USA</i> 92:11810-11813 (1995) ✓	
	C54	SCANLAN et al., <i>Cancer Lett.</i> 150:155-164 (2000) ✓	
	C55	SCANLAN, et al. <i>Int. J. Cancer</i> 98:485-492 (2002) ✓	
	C56	SCARCELLA et al., <i>Clin Cancer Res.</i> 5:335-41 (1999) ✓	
	C57	STEIMLE et al., <i>Genes Dev</i> 9:1021-32 (1995) ✓	
	C58	STOCKERT et al., <i>J Exp Med</i> 187:1349-1354 (1998) ✓	
	C59	TRaversari et al., <i>Immunogenetics</i> 35: 145-152 (1992) ✓	
	C60	TÜRECI et al., <i>Proc Natl Acad Sci USA</i> 95(9):5211-6 (1998) ✓	
	C61	VAN DEN EYNDE et al., <i>J Exp Med</i> 182: 689-698 (1995) ✓	
	C62	VAN DER BRUGGEN et al., <i>Science</i> 254:1643-1647 (1991) ✓	
	C63	VIDAEUS et al., <i>Mol Reprod Dev</i> 46:363-9 (1997) ✓	
	C64	VOLTZ et al., <i>N Engl J Med.</i> 340:1788-95 (1999) ✓	
	C65	ZENDMAN et al., <i>Cancer Res.</i> 1999, 59: 6223-6239 (1999) ✓	

EXAMINER

DATE CONSIDERED

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.